% | $
Quotes you view appear here for quick access.

Neurocrine Biosciences Inc. Message Board

ashtonb22000 454 posts  |  Last Activity: Mar 31, 2015 10:25 PM Member since: Jan 12, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • ashtonb22000 by ashtonb22000 Mar 31, 2015 10:25 PM Flag

    Not bad. Europe to follow?
    Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets
    SAN DIEGO, March 31, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it has entered into an exclusive collaboration and licensing agreement for the development and commercialization of its VMAT2 inhibitor, NBI-98854, in Japan and other select Asian markets with Mitsubishi Tanabe Pharma Corporation (TSE: 4508). Mitsubishi Tanabe intends to initially develop NBI-98854 in Japan for the chorea associated with Huntington's disease and tardive dyskinesia. Neurocrine retains full commercial rights to NBI-98854 in North America, Europe and other countries outside of Asia.

    Under the terms of the agreement, Neurocrine will receive an initial payment of $30 million and is eligible to receive up to $85 million in additional milestone payments associated with the development and commercialization of NBI-98854 in Asia. Upon commercialization, Neurocrine will receive royalties on product sales from Mitsubishi Tanabe territories in Asia. Neurocrine will also support Mitsubishi Tanabe's clinical efforts in developing NBI-98854 for patients suffering from the chorea associated with Huntington's disease and tardive dyskinesia.

    "We are excited to have one of the leading pharmaceutical companies in Japan as our commercialization partner for NBI-98854 in Asia. Importantly, Mitsubishi Tanabe has a proven track record of developing innovative pharmaceuticals, which we believe will optimize NBI-98854's full potential in the growing Asian movement disorders market," said Kevin Gorman, President and Chief Executive Officer of Neurocrine Biosciences. "We have recently initiated the build of our North American commercial infrastructure and the signing of this international partnership meaningfully extends that commercial reach. Additionally,

  • Reply to

    I sold half at $20 - somebody shoot me

    by endabaus Feb 11, 2015 10:00 AM
    ashtonb22000 ashtonb22000 Feb 12, 2015 8:29 PM Flag

    Pass it around, I sold about 80%

  • Reply to

    No takers Today??????????????

    by frogsleapmerlot Oct 21, 2014 9:54 AM
    ashtonb22000 ashtonb22000 Oct 21, 2014 5:55 PM Flag

    It is not like it wasn't expected and broadcasted at prior conferences. So I don't think the announcement is that significant and some might say the announcement is late (weren't they supposed to start in September?).

  • Reply to

    ARUN just ups Q4 guidance !!

    by pjinvestmentco May 22, 2014 4:57 PM
    ashtonb22000 ashtonb22000 May 22, 2014 7:27 PM Flag

    I used to post on this board a liltle while back and held a ton of shares. Back when it was in the 30s and down when it was in the 12s. No telling if I'm up or down at this point. now I mostly lurk. I just trade it now with a few thousands shares. I'm buying some after hours. Down 7% seems a bit much to me after this kind of report, but I've been wrong before. GLTA.

  • Reply to

    Everything remains on schedule and we're tanking?

    by eiretekk May 1, 2014 10:37 AM
    ashtonb22000 ashtonb22000 May 2, 2014 1:53 AM Flag

    Not dead money. The run up to Endo results in 4th quarter will be nice. I would not be surprised to see $18 to $20 before results are announced, if not higher. Biotech and the overall market in general can obviously affect it, but the anticipation for Endo results will be great.

  • Reply to

    A confession

    by doc_3377 Jan 7, 2014 10:24 PM
    ashtonb22000 ashtonb22000 Jan 7, 2014 11:15 PM Flag

    doc, it depends on what happens to Elagolix for Fibroids and Endo in July to September this year. If either of those fail, you will see low teens and more likely, single digits. If both are successful, $30+ will come fairly easily IMO. In the near term, I anticipate we will see $20 to $25 leading up to those results (much like the massive run up to VMAT phase II results in September). Phase III results for VMAT is probably a year away, at least.

  • ashtonb22000 ashtonb22000 Jan 7, 2014 6:44 PM Flag

    you are right frogs. So hard to find a meaningful post with all the garbage today.

  • Reply to

    We'll close $18.50 ......

    by mswrichmond Jan 7, 2014 11:53 AM
    ashtonb22000 ashtonb22000 Jan 7, 2014 6:38 PM Flag

    If results for Fibroids and Endo are positive later this year, $30 will be in the rear view mirror.

  • Reply to

    Printed $8.99

    by frogsleapmerlot Dec 17, 2013 2:08 PM
    ashtonb22000 ashtonb22000 Dec 24, 2013 1:32 AM Flag

    frogs, i hope i'm right, but I think you are discounting the run NBIX should have into elagolix results in 2014. I would hope it is similar, if not more, to VMAT.

  • Reply to


    by burnedoutprof Nov 14, 2013 3:44 PM
    ashtonb22000 ashtonb22000 Nov 15, 2013 10:57 AM Flag

    I don't think the UF trial completes until July.

  • Reply to

    Printed a $9.97 Handle

    by frogsleapmerlot Oct 15, 2013 12:09 PM
    ashtonb22000 ashtonb22000 Oct 18, 2013 12:52 AM Flag

    On other thing, a hope and prayer that VMAT Kinect 2 comes out favorable could change our fortunes more quickly. I'm not holding out much hope and it, if bad, it may ding us some more.

  • Reply to

    Printed a $9.97 Handle

    by frogsleapmerlot Oct 15, 2013 12:09 PM
    ashtonb22000 ashtonb22000 Oct 18, 2013 12:51 AM Flag

    I think we see some movement in later part of Q1. Assuming I'm correct, we'll have Fibroids and Endo results coming out between July and September respectively. Look at the long run up we had to VMAT phase II (with the help of a generous market though). With that being said, we probably are not more than a month or two apart.

  • Reply to

    Cheap. Great buying opportunity.

    by redshrimphunting Sep 10, 2013 7:16 PM
    ashtonb22000 ashtonb22000 Sep 12, 2013 12:34 PM Flag

    I wish redshrimp, but I don't think we see that range until next year as Endo results approach.

  • Reply to

    Upcoming Presentation is Bullish Signal

    by biotechveteran Sep 3, 2013 9:15 AM
    ashtonb22000 ashtonb22000 Sep 9, 2013 3:03 PM Flag

    Agree 100%. That last snafu may have been a blessing in disguise in the sense that they should have done everything possible to get the best results this time around.

  • Reply to

    should report results

    by bsdf7722 Sep 9, 2013 2:15 PM
    ashtonb22000 ashtonb22000 Sep 9, 2013 2:51 PM Flag

    According to NBIX's timeline, today was the first day that they should be expected. I assume it is possible that there could be some additional delay in analyzing the results, but that is really outside my area of expertise.

  • Reply to

    Upcoming Presentation is Bullish Signal

    by biotechveteran Sep 3, 2013 9:15 AM
    ashtonb22000 ashtonb22000 Sep 9, 2013 2:43 PM Flag

    If they had to analyze the results (review video, etc) like the last time, that could cause delay with the knowledge that there was a problem. I'm long with a big core position and i believe results will be good, but that doesn't mean I haven't considered selling some or the potential bad consequences. The stock ran up to the last VMAT results so I don't consider this run up a great indicator of how they will turn out this time. I certainly have enjoyed it though and hope it continues.

  • Reply to

    Upcoming Presentation is Bullish Signal

    by biotechveteran Sep 3, 2013 9:15 AM
    ashtonb22000 ashtonb22000 Sep 9, 2013 10:37 AM Flag

    If they don't release the results prior to the conference, would that be a bearish sign? It would be either because they are not ready or they don't want to be to discuss bad results at the conference.

  • Reply to

    Lambs among wolves...

    by opalockamishabob May 30, 2013 6:22 PM
    ashtonb22000 ashtonb22000 May 31, 2013 10:28 PM Flag

    Calm down Bill and Opal. I, for one, appreciate both of your posts (and Nclags as well). It is just more information that people like me to consider or disregard in my investing. I don't post much anymore, but keep an eye on the board. I have reduced myself to mostly trading ARUN. I was fortunate to have some short from the drop in the 20s to 17s, but I went long on 2,000 shares at 17 and sitting on loss there. I also shorted some for short term trade a few days ago and I let it get away from me this week. So I have losses both long and short. I feel the overall market may get ugly the next few months and that won't help ARUN. My guess is we will have to wait until the fall or end of year to see $17+ Just my gut talking so don't invest on it.

  • Reply to

    Up 15% A/H

    by opalockamishabob Feb 21, 2013 6:54 PM
    ashtonb22000 ashtonb22000 Feb 21, 2013 7:10 PM Flag

    I sold all my long traders a little early in after hours trading. I have to say I am in agreement with most of nclag's post about the future. However, near term, I think I'm in Opal's camp. The overall market is falling a little and if it continues, the high-beta ARUN will likely follow. I actually shorted just a few shares after hours, but I almost want those back because Nclag may be right about short squeeze and upgrades. Because I mainly trade ARUN, my thoughts are ARUN should fall some from its highs tomorrow. How far I don't know. I may short some with that expectation, but I'll definitely be looking to buy more long as I believe in the future that Nclag sees. I just hope I have some longs when the move up really happens. GLTA

  • Reply to

    in @ $21.70........

    by coolcatnip_44115 Feb 20, 2013 11:37 AM
    ashtonb22000 ashtonb22000 Feb 21, 2013 5:22 PM Flag

    I guess we sold a little early and left some extra money on the table.

47.31-0.35(-0.73%)Jul 2 4:00 PMEDT